PATENT CLAIM ANALYSIS

Application Number: 16025434
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-10
Patent Classification: ["435", "007230"]

Abstract:
The present invention relates to antigen recognizing constructs against a tumor associated antigen (TAA) derived from the target protein DDB1 and CUL4 associated factor 4-like 2 (DCAF4L2). The invention in particular provides novel T cell receptor (TCR) based molecules which are selective and specific for the TAA of the invention. The TCR of the invention, and TAA binding fragments derived therefrom, are of use for the diagnosis, treatment and prevention of TAA expressing cancerous diseases. Further provided are nucleic acids encoding the antigen recognizing constructs of the invention, vectors comprising these nucleic acids, recombinant cells expressing the antigen recognizing constructs and pharmaceutical compositions comprising the compounds of the invention.

Claim (Index 11):
A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of transformed cells expressing at least one vector encoding a T cell receptor (TCR),\n wherein the TCR comprises a complementary determining region (CDR) 3\u03b1 chain consisting of the amino acid sequences of SEQ ID NO: 3 and a CDR3\u03b2 chain consisting of the amino acid sequences of SEQ ID NO: 9, or a CDR3\u03b1 chain consisting of the amino acid sequences of SEQ ID NO: 15 and a CDR3\u03b2 chain consisting of the amino acid sequences of SEQ ID NO: 21, or a CDR3\u03b1 chain consisting of the amino acid sequences of SEQ ID NO: 27 and a CDR3\u03b2 chain consisting of the amino acid sequences of SEQ ID NO: 33, wherein the TCR is capable of binding to a peptide consisting of the amino acid sequence of ILQDGQFLV (SEQ ID NO: 49) in a complex with an MHC class I molecule, and wherein the cancer is selected from the group consisting of gastrointestinal or gastric cancer, acute lymphocytic cancer, acute myeloid leukemia, alveolar rhabdomyosarcoma, bone cancer, brain cancer, breast cancer, cancer of the anus, anal canal, or anorectum, cancer of the eye, cancer of the intrahepatic bile duct, cancer of the joints, cancer of the neck, gallbladder, or pleura, cancer of the nose, nasal cavity, or middle ear, cancer of the oral cavity, cancer of the vagina, cancer of the vulva, chronic lymphocytic leukemia, chronic myeloid cancer, colon cancer, esophageal cancer, cervical cancer, gastrointestinal carcinoid tumor, glioma, Hodgkin lymphoma, hypopharynx cancer, kidney cancer, larynx cancer, liver cancer, lung cancer, malignant mesothelioma, melanoma, multiple myeloma, nasopharynx cancer, non-Hodgkin lymphoma, cancer of the oropharynx, ovarian cancer, cancer of the penis, pancreatic cancer, peritoneum, omentum, and mesentery cancer, pharynx cancer, prostate cancer, rectal cancer, renal cancer, skin cancer, small intestine cancer, soft tissue cancer, stomach cancer, testicular cancer, thyroid cancer, cancer of the uterus, ureter cancer, and urinary bladder cancer.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 95.0
- Lexical Diversity: 1.82353
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15835095', '16023731', '15460654', '15677651', '15461020']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6486791040762785
- 35 USC 102 Novelty (BERT): 0.5384163672949882
- Combined Prediction Score: 0.6376528303981495
- Mean Citation Score: 346.617538
- Max Citation Score: 430.75974
- Similarity Product: 231.88278542313697

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test